Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
Appian (Nasdaq: APPN) and PSI CRO announced the launch of their first joint AI-powered process orchestration solution. The new offering automates clin...
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can pote...
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Or...
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, announced that it has received a Direct-to-Phase II Small Business Innov...
Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") announced that they have ent...
GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, announced the achievement of t...
ASTRIDE trial for first-line ES-SCLC demonstrated favorable median overall survival in serplulimab with chemotherapy versus atezo...
HighTide Therapeutics, Inc. (02511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapie...
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted...
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction,...
Advanced Clinical, a global clinical research organization (CRO) providing full-service clinical development, functional service provider (FSP) solutions a...
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...
© 2026 Biopharma Boardroom. All Rights Reserved.
